Thu 20 Aug 2026
All official websites of government entities in the Kingdom of Saudi Arabia end with.gov.sa.
Ensure the website is using the HTTPS protocol.
Registered with the Digital Government Authority under number:
| Study Title | Study Sponsor | Status | Study Drug | Trial Phase | Study Protocol Number | Site |
|---|---|---|---|---|---|---|
| A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer | King Faisal Specialist Hospital and Research Centre | Ongoing | DOCETAXEL Paclitaxel TAMOXIFEN Letrozole | 3 | S1007 | KFSH & RC-R |
| "A Phase III, Open-label, Randomized Study To Evaluate The Efficacy And Safety of Adjuvant Alectinib Versus Adjuvant Platinum-based Chemotherapy in Patients with Completely Resected Stage Ib (Tumors≥4 Cm) To Stage IIIa Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer " | Roche | Completed | ALECTINIB | 3 | BO40336 | KFSH&RC-R |
| A Phase III, Multicentre, International, Randomised, Parallel Group, Double Blind Cardiovascular Safety Study of BI 10773 (10 mg and 25 mg Administered Orally Once Daily) Compared to Usual Care in Type 2 Diabetes Mellitus Patients With Increased Cardiovascular Risk | Boehringer Ingelheim | Completed | BI 10773 | 3 | 1245.25 | KFMC |
| A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib Compared with Teriflunomide, in Participants with Relapsing Multiple Sclerosis to Evaluate Efficacy and Safety. | Merck | Ongoing | Evobrutinib | 3 | MS200527ˍ0082 | King Faisal Specialist Hospital and Research Center (Jeddah) |
| "A phase III, Multicenter, Randomized, Double-blind Study to Assess Efficacy and Safety of Two Doses of Crizanlizumab versus placebo, with or without Hydroxyurea/Hydroxycarbamide Therapy, in Adolescent and Adult Sickle Cell Disease Patients with Vaso-Occlusive Crises (STAND)" | Novartis | Ongoing | Crizanlizumab | 3 | CSEG101A2301 | King Fahad Medical City (Riyadh) |
| A PHASE III, MULTICENTER, RANDOMISED, DOUBLEBLIND, PLACEBOCONTROLLED STUDY OF ATEZOLIZUMAB (ANTI−PDL1 ANTIBODY) IN COMBINATION WITH PACLITAXEL COMPARED WITH PLACEBO WITH PACLITAXEL FOR PATIENTS WITH PREVIOUSLY UNTREATED INOPERABLE LOCALLY ADVANCED OR METASTATIC TRIPLE NEGATIVE BREAST CANCER | Roche | Completed | ATEZOLIZUMAB / PACLITAXEL | 3 | MO39196 | IMC (Closed), KFSH (Closed), KFMC (Closed) |
| A Phase III, Multicenter, Double-Blind, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy of Sitagliptin in Pediatric Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control | MSD | Ongoing | Sitagliptin | 3 | MK0431-083 | NGHA-R |
| A Phase III, Multicenter, Double-Blind, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-0431A (A Fixed-Dose Combination Tablet of Sitagliptin and Metformin) in Pediatric Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Therapy (Alone or in Combination With Insulin) | MSD | Completed | MK-0431A (Sitagliptin / Metformin) | 3 | MK0431-170 | NGHA-R |
| A Phase III, Double-Blind, Randomised Study to Assess the Efficacy and Safety of AZD9291 versus a Standard of Care Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with Epidermal Growth Factor Receptor Mutation Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer | AstraZeneca | Completed | AZD9291 | 3 | D5160C00007 | KFSH&RC-R |
| A Phase III Study of Trastuzumab Deruxtecan (T-DXd) with or without Pertuzumab versus Taxane, Trastuzumab and Pertuzumab in HER2-positive, First-line Metastatic Breast Cancer (DESTINY-Breast09) | Astrazeneca | Ongoing | Trastuzumab-deruxtecan (Enhertu) | 3 | D967UC00001 | King Fahad Specialist Hospital (Dammam) |
Last update date: 08/05/2025 at 03:17 PM Saudi Arabia time
No feedback has been submitted for this page yet.
Comments and Suggestions
For any inquiries or comments about the government services, please fill in the required information.